The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center

NCT07552285 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Soochow University

Phase

Observational

Started

2025-05-01

Last updated

2026-04-27

Condition(s) studied

Prostate CancerProstate Cancer (Diagnosis)

Investigational drug(s) / intervention(s)

observational study

observational study: The researchers will conduct observations, collect data and conduct follow-ups on the participants, but will not actively alter their treatment or health conditions.

Study summary

The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is:

Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.

Eligibility

Sex

MALE

Min age

20 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: 1. Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels; 2. Patients with no prior history of other tumors; 3. Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates. Exclusion Criteria: 1. The patient has a history of malignant tumors and has received corresponding treatment; 2. Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.; 3. Patients who have previously undergone radical prostatectomy for prostate cancer.

Primary outcome measure(s)

Microstructure parameters related to the OGSE sequence — Within one week after the MRI scan
CEST sequence-related numerical values — Within one week after the MRI scan
MAGIC sequence-related numerical values — Within one week after the MRI scan
IVIM sequence-related numerical values — Within one week after the MRI scan

Trial sites (1)

Facility	City	Region	Status
The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu	Recruiting

More The First Affiliated Hospital of Soochow University trials in China

Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia Recruiting

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Recruiting

Olverembatinib for FGFR1-rearranged Neoplasms Recruiting

A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia Recruiting

N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy Active, not recruiting

Other trials for the same condition

Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7% Recruiting

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02) Recruiting

Adjuvant Chemotherapy for High Malignant Prostate Cancer Recruiting

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer Active, not recruiting

Ipsilateral Versus Bilateral Systematic Biopsy Combined With MRI/Ultrasound Cognitive Fusion Targeted Biopsy for Prostate Cancer Diagnosis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07552285 on ClinicalTrials.gov ↗ ← All trials in China